{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 420466712
| IUPAC_name = 3-<nowiki/>{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1''H'',3''H'')-dione
| image = Ketanserin.png
| width = 250
<!--Clinical data-->
| tradename = Sufrexal
| Drugs.com = {{drugs.com|international|ketanserin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 74050-98-9
| ATC_prefix = C02
| ATC_suffix = KD01
| ATC_supplemental =   {{ATCvet|D03|AX90}}
| PubChem = 3822
| IUPHAR_ligand = 88
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3690
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 97F9DE4CT4
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02363
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 6123
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 51
<!--Chemical data-->
| chemical_formula =
| C=22 | H=22 | F=1 | N=3 | O=3
| molecular_weight = 395.43 g/mol
| smiles = c1ccc2c(c1)c(=O)n(c(=O)[nH]2)CCN3CCC(CC3)C(=O)c4ccc(cc4)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FPCCSQOGAWCVBH-UHFFFAOYSA-N
| synonyms = R41468; R-41468; R-41,468
}}

'''Ketanserin''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) (brand name '''Sufrexal'''; former developmental code name '''R41468''') is a [[drug]] used clinically as an [[antihypertensive agent]] and in [[scientific research]] to study the [[serotonin]] system; specifically, the [[5-HT2 receptor|5-HT<sub>2</sub> receptor family]].<ref name="Ahuja2005">{{cite book|author=Gopi Doctor Ahuja|title=Drug Injury: Liability, Analysis, and Prevention|url=https://books.google.com/books?id=EB00rD8AqaYC&pg=PA304|year=2005|publisher=Lawyers & Judges Publishing Company|isbn=978-0-913875-27-8|pages=304–}}</ref> It was discovered at [[Janssen Pharmaceutica]] in 1980.<ref name="Healy2009">{{cite book|author=David Healy|title=The Creation of Psychopharmacology|url=https://books.google.com/books?id=6O2rPJnyhj0C&pg=PA252|date=1 July 2009|publisher=Harvard University Press|isbn=978-0-674-03845-5|pages=252–253}}</ref><ref name="Schwartz1989">{{cite book|author=Harry Schwartz|title=Breakthrough: the discovery of modern medicines at Janssen|url=https://books.google.com/books?id=hwhtAAAAMAAJ|date=August 1989|publisher=Skyline Pub. Group|isbn=978-1-56019-100-1|page=74}}</ref>

==Medical use==
Ketanserin is classified as an [[antihypertensive]] by the [[World Health Organization]]<ref>[http://www.whocc.no/atc_ddd_index/?code=C02KD01 ATC/DDD Index<!-- Bot generated title -->]</ref> and the [[National Institute of Health]].<ref>[http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?mode=&term=Ketanserin Ketanserin<!-- Bot generated title -->]</ref>

It has been used to reverse pulmonary hypertension caused by [[protamine]] (which in turn was administered to reverse the effects of [[heparin]] overdose).<ref name="pmid8969033">{{cite journal |vauthors=van der Starre PJ, Solinas C |title=Ketanserin in the treatment of protamine-induced pulmonary hypertension |journal=Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital |volume=23 |issue=4 |pages=301–4 |year=1996 |pmid=8969033 |pmc=325377 |doi= |url=}}</ref>

The reduction in hypertension is not associated with reflex tachycardia.<ref name="pmid2786422">{{cite journal |vauthors=Hodsman NB, Colvin JR, Kenny GN |title=Effect of ketanserin on sodium nitroprusside requirements, arterial pressure control and heart rate following coronary artery bypass surgery |journal=British journal of anaesthesia |volume=62 |issue=5 |pages=527–31 |date=May 1989 |pmid=2786422 |doi= 10.1093/bja/62.5.527|url=http://bja.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=2786422}}</ref>

It has been used in cardiac surgery.<ref name="pmid19058975">{{cite journal |vauthors=Elbers PW, Ozdemir A, van Iterson M, van Dongen EP, Ince C |title=Microcirculatory Imaging in Cardiac Anesthesia: Ketanserin Reduces Blood Pressure But Not Perfused Capillary Density |journal=J. Cardiothorac. Vasc. Anesth. |volume= 23|issue= 1|pages= 95–101|date=December 2008 |pmid=19058975 |doi=10.1053/j.jvca.2008.09.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S1053-0770(08)00294-2}}</ref>

==Research use==
With [[tritium]] (<sup>3</sup>H) [[Radioactivity|radioactively]] labeled ketanserin is used as a [[radioligand]] for serotonin 5-HT<sub>2</sub> receptors, e.g. in [[ligand binding assay|receptor binding assay]]s and [[autoradiography]].<ref name="pmid17182260">{{cite journal | vauthors = Eickhoff SB, Schleicher A, Scheperjans F, Palomero-Gallagher N, Zilles K | title = Analysis of neurotransmitter receptor distribution patterns in the cerebral cortex | journal = NeuroImage | volume = 34 | issue = 4 | pages = 1317–30 | year = 2007 | pmid = 17182260 | doi = 10.1016/j.neuroimage.2006.11.016 | url = }}</ref> This radio-labeling has enabled the study of serotonin [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[gene expression|distribution]] in the [[human brain]].<ref name="pmid3601071">{{cite journal | vauthors = Pazos A, Probst A, Palacios JM | title = Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors | journal = Neuroscience | volume = 21 | issue = 1 | pages = 123–39 | year = 1987 | pmid = 3601071 | doi = 10.1016/0306-4522(87)90327-7| url = }}</ref>

An autoradiography study of the human [[cerebellum]] has found an increasing binding of <sup>3</sup>H-ketanserin with [[aging|age]] (from below 50 [[Molarity|femtomol]] per milligram tissue at around 30 years of age to over 100 above 75 years).<ref name="pmid11574947">{{cite journal | vauthors = Eastwood SL, Burnet PW, Gittins R, Baker K, Harrison PJ | title = Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia | journal = Synapse | volume = 42 | issue = 2 | pages = 104–14 | year = 2001 | pmid = 11574947 | doi = 10.1002/syn.1106 | url = }}</ref> The same research team found no significant correlation with age in their [[homogenization (biology)|homogenate]] binding study.

Ketanserin has also been used with [[carbon]] (<sup>11</sup>C) [[Radioactivity|radioactively]] labeled NNC112 in order to image cortical [[Dopamine receptor D1|D<sub>1</sub> receptors]] without contamination by 5-HT<sub>2</sub> receptors.<ref>{{cite journal | title=Imaging cortical dopamine D1 receptors using 11C NNC112 and ketanserin blockade of the 5-HT 2A receptors |vauthors=Catafau AM, Searle GE, Bullich S, Gunn RN, Rabiner EA, Herance R, Radua J, Farre M, Laruelle M | journal=J Cereb Blood Flow Metab | url=http://www.nature.com/jcbfm/journal/v30/n5/full/jcbfm2009269a.html | volume = 30 | pages = 985–93 | year=2010 | doi=10.1038/jcbfm.2009.269 | pmid=20029452 | issue=5 | pmc=2949183}}</ref>

==Pharmacology==
Ketanserin is a high-affinity non-selective [[receptor antagonist|antagonist]] of [[5-HT2 receptor|5-HT<sub>2</sub> receptors]] in rodents,<ref name="NIMH-PDSP">[http://pdsp.med.unc.edu/ NIMH Psychoactive Drug Screening Program]</ref><ref>{{cite journal | title=Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats |author1=Creed-Carson M |author2=Oraha A. Norbrega JN. | journal=Behav Brain Res | url=http://www.sciencedirect.com/science/article/pii/S0166432811000519 | volume=219 | pages = 273–279 | year = 2011 | doi = 10.1016/j.bbr.2011.01.025 | pmid =21262266}}</ref> with K<sub>i</sub> values of 2–3&nbsp;nM for the 5-HT<sub>2A</sub> receptor and 28&nbsp;nM for the 5-HT<sub>2C</sub> receptor).<ref name="NIMH-PDSP"/><ref name="Meneses2014">{{cite book|author=Alfredo Meneses|title=The Role of 5-HT Systems on Memory and Dysfunctional Memory: Emergent Targets for Memory Formation and Memory Alterations|url=https://books.google.com/books?id=x_TJAgAAQBAJ&pg=PA23|date=11 March 2014|publisher=Elsevier Science|isbn=978-0-12-801083-9|pages=23–}}</ref> In primates including humans however, ketanserin is a more selective antagonist of the 5-HT<sub>2A</sub> over the 5-HT<sub>2C</sub> receptor,<ref name="NIMH-PDSP"/> with K<sub>i</sub> values of 2–3&nbsp;nM for the  5-HT<sub>2A</sub>receptor and 130&nbsp;nM for the 5-HT<sub>2C</sub> receptor.<ref name="NIMH-PDSP"/> In addition to the 5-HT<sub>2</sub> receptors, ketanserin is also a high affinity antagonist for the [[H1 receptor|H<sub>1</sub> receptor]] (K<sub>i</sub> = 2 nM),<ref name="NIMH-PDSP" /><ref name="Coyne2008">{{cite book|author=C.P. Coyne|title=Comparative Diagnostic Pharmacology: Clinical and Research Applications in Living-System Models|url=https://books.google.com/books?id=Kar-JGFMe-AC&pg=PA104|date=9 January 2008|publisher=John Wiley & Sons|isbn=978-0-470-34429-3|pages=104–}}</ref> and has measurable albeit relatively low affinity for a number of other receptors:

* [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic]] receptors (K<sub>i</sub> = ~40 nM)<ref name="Coyne2008" /> 
* [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic]] receptors = ~200 nM) {{citation needed|date=April 2016}}
* [[5-HT1D receptor|5-HT<sub>1D</sub>]] receptors  (K<sub>i</sub> = ? nM) <ref name="Meneses2014" /><ref name="OlivierWijngaarden1997">{{cite book|author1=B. Olivier|author2=I. van Wijngaarden|author3=W. Soudijn|title=Serotonin Receptors and their Ligands|url=https://books.google.com/books?id=lfo0hGqIex0C&pg=PA118|date=10 July 1997|publisher=Elsevier|isbn=978-0-08-054111-2|pages=118–}}</ref> 
* [[5-HT2B receptor|5-HT<sub>2B</sub>]] receptors  (K<sub>i</sub> = ? nM)<ref name="Chapman2007">{{cite book|author=Mark Chapman|title=Evaluation of the Role of Serotonin in Pulmonary Arterial Hypertension in Broilers Induced by Bacterial Lipopolysaccharide and Cellulose Microparticles|url=https://books.google.com/books?id=FqsS2b5iwi8C&pg=PA31|year=2007|publisher=ProQuest|isbn=978-0-549-36052-0|pages=31–}}</ref> 
* [[5-HT6 receptor|5-HT<sub>6</sub>]] receptors  (K<sub>i</sub> = ~300 nM)<ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA388|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=388–}}</ref> 
* [[5-HT7 receptor|5-HT<sub>7</sub>]] receptors (K<sub>i</sub> = ? nM)<ref name="Meneses2014" /> 
* [[D1 receptor|D<sub>1</sub>]] receptors (~300 nM)<ref name="Coyne2008" /> 
* [[D2 receptor|D<sub>2</sub>]] receptors (K<sub>i</sub> = ~500 nM) [[receptor (biochemistry)|receptor]]s.<ref name="NIMH-PDSP" /><ref name="Coyne2008" />

It has also been found to block the [[vesicular monoamine transporter 2]] (VMAT2).<ref name="MullerJacobs2009">{{cite book|author1=Christian P. Muller|author2=Barry Jacobs|title=Handbook of the Behavioral Neurobiology of Serotonin|url=https://books.google.com/books?id=aomaKqIE1jUC&pg=PA592|date=30 December 2009|publisher=Academic Press|isbn=978-0-08-087817-1|pages=592–}}</ref><ref>{{cite book|title=Catecholamines: Bridging Basic Science with Clinical Medicine: Bridging Basic Science with Clinical Medicine|url=https://books.google.com/books?id=sNQ7IA3y2kAC&pg=PA237|date=20 October 1997|publisher=Academic Press|isbn=978-0-08-058134-7|pages=237–}}</ref>

==See also==
* [[Altanserin]]
* [[Ritanserin]]

==References==
{{Reflist|2}}

{{Antihypertensives}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Serotonin receptor modulators}}
}}

[[Category:Alpha-1 blockers]]
[[Category:Alpha-2 blockers]]
[[Category:Antihypertensive agents]]
[[Category:5-HT1D antagonists]]
[[Category:5-HT2A antagonists]]
[[Category:5-HT2C antagonists]]
[[Category:5-HT6 antagonists]]
[[Category:5-HT7 antagonists]]
[[Category:D1 antagonists]]
[[Category:D2 antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Janssen Pharmaceutica]]
[[Category:Ketones]]
[[Category:Fluoroarenes]]
[[Category:Piperidines]]
[[Category:Quinazolinones]]
[[Category:VMAT inhibitors]]